S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Coherus BioSciences (CHRS) Stock Forecast, Price & News

+0.36 (+4.74%)
(As of 05/13/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.50 million shs
Average Volume
918,320 shs
Market Capitalization
$615.51 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Coherus BioSciences logo

About Coherus BioSciences

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$326.55 million
Book Value
$0.16 per share


Net Income
$-287.10 million
Pretax Margin




Free Float
Market Cap
$615.51 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.18 out of 5 stars

Medical Sector

381st out of 1,403 stocks

Biological Products, Except Diagnostic Industry

63rd out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences
or view top-rated stocks.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Coherus BioSciences

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its quarterly earnings results on Thursday, February, 17th. The biotechnology company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.01. The biotechnology company had revenue of $73.37 million for the quarter, compared to the consensus estimate of $83.32 million. Coherus BioSciences had a negative net margin of 69.24% and a negative trailing twelve-month return on equity of 211.68%. During the same period in the previous year, the company earned $0.12 earnings per share.
View Coherus BioSciences' earnings history

What price target have analysts set for CHRS?

5 Wall Street analysts have issued 12 month price objectives for Coherus BioSciences' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Coherus BioSciences' stock price to reach $22.40 in the next twelve months. This suggests a possible upside of 181.8% from the stock's current price.
View analysts' price targets for Coherus BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?
Coherus BioSciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 67, Pay $1.86M) (LinkedIn Profile)
  • Mr. McDavid Stilwell, Chief Financial Officer (Age 50, Pay $756k) (LinkedIn Profile)
  • Mr. Vladimir Vexler Ph.D., Chief Scientific Officer (Age 64, Pay $778.28k) (LinkedIn Profile)
  • Mr. Richard L. Hameister, Chief Technical Officer
  • Mr. Thomas F. Fitzpatrick, Chief Legal Officer
  • Cheston Turbyfill, VP of Communications
  • Mr. Chris Thompson, Exec. VP of Sales
  • Ms. Rebecca Sunshine, Exec. VP of HR (Age 59)
  • Mr. Michael A. Fleming, Chief Strategy Officer
  • Mr. Michael Chen, Sr. VP of Commercial Analytics & Trade
What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.59%), Vanguard Group Inc. (6.12%), Peregrine Capital Management LLC (1.22%), Thompson Siegel & Walmsley LLC (0.91%), Northern Trust Corp (0.91%) and Citigroup Inc. (0.88%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences

Which institutional investors are selling Coherus BioSciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Bank of New York Mellon Corp, Citigroup Inc., South Dakota Investment Council, Group One Trading L.P., American Century Companies Inc., SG Americas Securities LLC, and Principal Financial Group Inc.. Company insiders that have sold Coherus BioSciences company stock in the last year include Dennis M Lanfear, James Healy, and Mcdavid Stilwell.
View insider buying and selling activity for Coherus BioSciences
or view top insider-selling stocks.

Which institutional investors are buying Coherus BioSciences stock?

CHRS stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vanguard Group Inc., BlackRock Inc., Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Royce & Associates LP, Sei Investments Co., and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for Coherus BioSciences
or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $7.95.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $615.51 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.